Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Inventory (2018 - 2025)

Historic Inventory for Akebia Therapeutics (AKBA) over the last 8 years, with Q3 2025 value amounting to $18.6 million.

  • Akebia Therapeutics' Inventory fell 902.75% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 902.75%. This contributed to the annual value of $16.2 million for FY2024, which is 351.79% up from last year.
  • Akebia Therapeutics' Inventory amounted to $18.6 million in Q3 2025, which was down 902.75% from $16.7 million recorded in Q2 2025.
  • Akebia Therapeutics' Inventory's 5-year high stood at $45.2 million during Q3 2022, with a 5-year trough of $15.7 million in Q4 2023.
  • Its 5-year average for Inventory is $27.3 million, with a median of $21.6 million in 2022.
  • Per our database at Business Quant, Akebia Therapeutics' Inventory crashed by 6376.97% in 2021 and then surged by 3429.71% in 2022.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Inventory stood at $36.6 million in 2021, then crashed by 41.12% to $21.6 million in 2022, then decreased by 27.25% to $15.7 million in 2023, then rose by 3.52% to $16.2 million in 2024, then grew by 14.78% to $18.6 million in 2025.
  • Its Inventory stands at $18.6 million for Q3 2025, versus $16.7 million for Q2 2025 and $19.7 million for Q1 2025.